UiPath Inc. provides an end-to-end automation platform offering a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company is headquartered in New York, New York.
| Revenue (TTM) | $1.67B |
| Gross Profit (TTM) | $1.39B |
| EBITDA | $123.63M |
| Operating Margin | 7.27% |
| Return on Equity | 18.20% |
| Return on Assets | 2.37% |
| Revenue/Share (TTM) | $3.14 |
| Book Value | $3.66 |
| Price-to-Book | 2.95 |
| Price-to-Sales (TTM) | 3.60 |
| EV/Revenue | 2.626 |
| EV/EBITDA | 35.89 |
| Quarterly Earnings Growth (YoY) | 105.70% |
| Quarterly Revenue Growth (YoY) | 17.30% |
| Shares Outstanding | $453.43M |
| Float | $410.04M |
| % Insiders | 9.55% |
| % Institutions | 83.38% |
Volatility is currently expanding
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Marvell Technology is a leader in data center infrastructure, benefiting from massive strategic investments in AI networking. UiPath has established a strong presence in agentic automation, helping enterprise customers streamline complex business workflows.
SNPS is among U.S. robotics plays as 2026 brings major advances in physical AI, surgical systems, defense autonomy and space robotics.
Marvell Technology generates much higher overall revenue volume compared to UiPath, maintaining a clear size advantage over the tracked period. Both companies have mostly seen their total revenue increase steadily year over year, though they experience slight quarter-over-quarter dips at different times of the calendar year.
UiPath (NYSE:PATH | PATH Price Prediction) has quietly become one of the more interesting orphans in enterprise software.
UiPath's AI orchestration strategy, improving profitability and attractive valuation make it stand out over AppLovin despite both benefiting from AI adoption.
PATH's ARR increased from $1.46 billion to $1.9 billion through Q1 2027, reflecting resilient enterprise demand for AI-powered automation despite ongoing concerns over software spending.
UiPath faces near-term headwinds as AI-powered automation sparks fears of legacy RPA cannibalization before Maestro can drive net-new growth. PATH achieved full-year and first-quarter FY 2027 GAAP profitability for the first time, but investors are concerned about net income volatility. The stock trades at a TTM P/S of 3.85, below historical medians, reflecting market skepticism about revenue growth and the SaaS sector's sentiment downturn.
UiPath (PATH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
UiPath is rated a buy at $12, trading at 15x FY2027 and 13x FY2028 earnings, with strong 80%+ gross margins. Revenue grew 17% to $418M in Q1 FY2027, ARR rose 12% to $1.9B, and non-GAAP operating margin reached 22%. Agentic automation (Maestro) is UiPath's key catalyst, but AI monetization is unproven; net retention at 109% needs to improve for higher growth.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PATH and any ticker you trade — then tracks every position and per-strategy win rate.
